Physician profile
Julia C Young
NPI 1023024163
$559.51
in general payments reported to CMS, 2019-2025
16 companies · $66.45 in 2025
The $66.45 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $28.33 · 2021: $75.39 · 2022: $148 · 2023: $42.40 · 2024: $15.99 · 2025: $66.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $96.01 | 2019-2022 | |
| Pfizer INC. | $74.00 | 2019-2024 | |
| Sanofi Pasteur INC. | $62.74 | 2021-2025 | |
| Glaxosmithkline, LLC. | $60.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.95 | 2019-2022 | |
| Corium, LLC | $28.34 | 2021 | |
| Tris Pharma INC | $28.33 | 2020 | |
| Alk-Abello, INC | $27.52 | 2025 | Neffy |
| Cranial Technologies, INC | $26.51 | 2022 | |
| Sobi, INC | $22.16 | 2019 | |
| Novo Nordisk INC | $18.63 | 2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $17.33 | 2023 | Wavewriter Alpha Prime 16 |
| Neos Therapeutics, LP | $16.74 | 2019 | |
| Abbvie INC. | $13.69 | 2022 | |
| Kaleo, INC. | $12.68 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.